| Code | CSB-RA003658MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of empasiprubart (ARGX-117), targeting complement component C2, a soluble complement protein that is essential to the classical and lectin pathways. Upon pathway activation, C2 associates with C4b to form the C4bC2 (C3 proconvertase) complex, which is then processed to generate the C3 convertase (C4b2a)—a central enzymatic step that amplifies complement activation and drives downstream effector processes such as opsonization, inflammatory mediator release, and terminal pathway activation.
Empasiprubart is described as a humanized “sweeping” anti-C2 monoclonal antibody with pH- and Ca²⁺-dependent binding, designed to inhibit C2 function and thereby block classical/lectin pathway activation upstream of C3 by preventing formation of the C4bC2 complex. This biosimilar enables researchers to investigate C2-driven complement biology, including pathway initiation/amplification mechanisms and complement-dependent injury models, and to develop/benchmark assays that quantify classical/lectin pathway inhibition (e.g., C3 deposition readouts) in controlled experimental systems.
There are currently no reviews for this product.